GCM
URGN icon

Graham Capital Management’s UroGen Pharma URGN Stock Holding History

Graham Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-23,571
Closed -$470K – 1601
2025
Q3 		$470K Buy
+23,571
New +$423K 0.01% 639

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Graham Capital Management's URGN Position: Q4 2025 in Review

Graham Capital Management sold out of UroGen Pharma (URGN) in Q4 2025, closing a stake of 23,571 shares — an estimated $470K sold.

Graham Capital Management first reported a position in URGN in Q3 2025 and held it in 1 quarter. The position peaked at $470K in Q3 2025. 167 funds tracked by Wall St. Rank hold URGN as of Q4 2025.

  • Graham Capital Management reported no remaining UroGen Pharma position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 23,571 UroGen Pharma shares in Q4 2025, an estimated $470K.
  • Graham Capital Management first reported a position in UroGen Pharma in Q3 2025 and held it in 1 quarter.
  • Graham Capital Management's UroGen Pharma position peaked at $470K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.